Shandong Sanyuan Biotechnology Co., Ltd
Initial public offering and listing on GEM
Suggestive announcement of listing announcement
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
With the approval of Shenzhen Stock Exchange, the RMB common shares issued by the company will be listed on the gem of Shenzhen Stock Exchange on February 10, 2022. The full text of the listing announcement and the full text of the IPO and listing on the gem will be disclosed on the information disclosure website designated by the CSRC: cninfo.com, www.cn info. com. cn.； China Securities Network, website: www.cs.com com. cn.； China Securities Network, website: www.cn stock. com.； Securities Times website, www.stcn.com com.； Securities Daily website, www.zqrb.com cn.； QR code of the website: cninfo, for investors to check. 1、 Listing overview
(I) stock abbreviation: Sanyuan biology
(II) Stock Code: 301206
(III) total share capital after IPO: 134883800 shares
(IV) increased shares from initial public offering: 33721000 shares II. Risk warning
The company’s shares will be listed on the growth enterprise market of Shenzhen Stock Exchange, which has high investment risk. GEM companies have the characteristics of unstable performance, high operation risk and high delisting risk, and investors are facing greater market risk. Investors should fully understand the investment risks of the gem and the risk factors disclosed by the company, and make investment decisions prudently.
The offering price is 109.30 yuan / share, which does not exceed the median and weighted average of offline investors’ quotations after excluding the highest quotation, as well as the Securities Investment Fund (hereinafter referred to as “public fund”) and the National Social Security Fund (hereinafter referred to as “social security fund”) established through public offering after excluding the highest quotation The lower of the median and weighted average of the quoted prices of the basic endowment insurance fund (hereinafter referred to as “pension”), the enterprise annuity fund established in accordance with the measures for the administration of enterprise annuity fund (hereinafter referred to as “enterprise annuity fund”) and the insurance fund (hereinafter referred to as “insurance fund”) in accordance with the measures for the administration of the use of insurance funds. According to the industry classification guidelines for listed companies (revised in 2012) issued by the China Securities Regulatory Commission, the industry of the company is food manufacturing, and the industry code is “C14”. As of January 18, 2022 (T-4), the average static P / E ratio of the industry released by China Securities Index Co., Ltd. in the latest month is 43.85 times.
As of January 18, 2022 (T-4), the valuation levels of comparable listed companies are as follows:
The closing price of T-4 stock in 2020 minus the static securities corresponding to the deduction in 2020 is referred to as the securities code for short (yuan non front EPS non rear EPS P / E ratio minus non P / E ratio minus non / share) (yuan / share) (yuan / share) before (2020) and after (2020) Baolingbao Biology Co.Ltd(002286) 002286 SZ 13.10 0.1341 0.0975 97.71 134.36
Zhejiang Huakang Pharmaceutical Co.Ltd(605077) 605077. SH 42.43 1.8823 1.7818 22.54 23.81
Anhui Jinhe Industrial Co.Ltd(002597) 002597. SZ 43.29 1.2810 1.0163 33.79 42.60
Average 51.35 66.92
Data source: wind information, data as of January 18, 2022 (T-4).
Note 1: if there is mantissa difference in the calculation of P / E ratio, it is caused by rounding;
Note 2: EPS before / after deduction of non recurring profit and loss in 2020 = net profit attributable to the parent before / after deduction of non recurring profit and loss in 2020 / total share capital on T-4 day. The issuance price of 109.30 yuan / share corresponds to the lower diluted P / E ratio of the issuer before and after deducting non recurring profits and losses in 2020, which is 63.39 times higher than the average static P / E ratio of the industry in the latest month published by China Securities Index Co., Ltd. and lower than the average static P / E ratio of comparable companies after deducting non recurring profits and losses in 2020, However, there is still a risk that the decline of the issuer’s share price will bring losses to investors in the future.
There is a risk that the net asset scale will increase significantly due to the acquisition of raised funds, which will have an important impact on the issuer’s production and operation mode, operation management and risk control ability, financial status, profitability and long-term interests of shareholders. The issuer and the recommendation institution (lead underwriter) remind investors to pay attention to investment risks, carefully study and judge the rationality of issuance pricing, and make investment decisions rationally.
The company reminds investors to pay attention to the investment risks in the initial stage of IPO (hereinafter referred to as “new shares”), and investors should fully understand the risks and rationally participate in the trading of new shares.
3、 Contact information
(I) contact address and telephone number of the issuer
Issuer: Shandong Sanyuan Biotechnology Co., Ltd
Contact address: No. 89, ZhangFu Road, Binbei, Binzhou City, Shandong Province
Contact: Wei Zhongyong
Tel: 0543-3529859
Fax: 0543-3529850
(II) contact address and telephone number of the lead underwriter and the sponsor representative
Sponsor (lead underwriter): China Securities Co.Ltd(601066)
Sponsor representatives: Lu danjun, Chen Lei
Address: second and third floors, blocks B and E, Kaiheng Center, No. 2 chaonei street, Dongcheng District, Beijing
Tel: 010-65608208
Fax: 010-65608450
(there is no text on this page, which is the seal page of the suggestive announcement of the listing announcement of Shandong Sanyuan Biotechnology Co., Ltd. on its initial public offering and listing on the GEM)
The third page of the announcement of Shandong Biotechnology Co., Ltd. on the date of initial public offering of shares of Shandong Biotechnology Co., Ltd. (without the seal of the third page of the notice of Shandong Biotechnology Co., Ltd.)
China Securities Co.Ltd(601066) mm / DD / yy
